Skip to Content

Nordson Corp

NDSN: XNAS (USA)
View Stock Summary
Morningstar Rating for Stocks Fair Value Economic Moat Capital Allocation
$621.00GjsbtlGbcggzq

Nordson Earnings: Headwinds in Semiconductor and Biopharma End Markets Weigh on Revenue Growth

Narrow-moat-rated Nordson’s fiscal third-quarter adjusted EPS declined by 6% from the prior-year period, from $2.49 to $2.35, as the firm continued to face headwinds in the semiconductor and biopharma end markets. We’ve maintained our $237 fair value estimate, as our slightly more muted near-term revenue growth projections were offset by time value of money.

Free Trial of Morningstar Investor

Get our analysts’ objective, in-depth, and continuous investment coverage of NDSN so you can make buy / sell decisions free of market noise.

Start Free Trial

Sponsor Center